UNASSIGNED: Current clinical practice guidelines recommend dosing anti- @entity378 drugs according to ideal body weight and provide dosing caps for most first-line agents. However, this recommendation may be placing corpulent @entity1 with @entity378 at risk as increased total body weight is associated with an increased risk of clinical failure. @entity1 with @entity6 are at an increased risk of developing @entity378 and typically weigh more than @entity1 with @entity378 alone. All these factors in-combination stress the importance of evaluating the effect of weight on the pharmacokinetics of first-line anti- @entity378 drugs. Multiple studies suggest the use of total body weight based dosing for @entity1215 . Less data are available for @entity5585 and @entity3110 , but both appear to be candidates for total body weight based dosing. The study evaluating @entity5553 concluded that no adjustment is required. However, the larger variability in @entity28 @entity1 is concerning as to whether "one size fits all" dosing is optimal for @entity5553 . The vast majority of the @entity3109 's pharmacokinetic variability is due to @entity6867 *4 status. However, more extensive analysis of slow and fast metabolizers is needed to determine the effect of weight within each subgroup. @entity3477 does not appear to be affected by weight, but doses of at least 800 mg are likely needed to optimize its pharmacokinetic/pharmacodynamic target attainment. Future pharmacokinetic evaluations should focus on recruiting a wide range of @entity1 weights. These analyses should take advantage of the full weight distribution instead of arbitrarily dichotomizing @entity1 into @entity28 vs. @entity28 @entity1 . A subsequent evaluation of the safety and effectiveness of optimized dosing regimens is needed.

Evolving Larger: Dosing XXXX ( @entity378 ) Drugs in an Obese World.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'persons'] @entity3110 :: ('MESH:D004977', 'Chemical') :: ['ethambutol'] @entity5585 :: ('MESH:D011718', 'Chemical') :: ['pyrazinamide'] @entity3477 :: ('MESH:C104727', 'Chemical') :: ['Moxifloxacin'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese', 'non-obese'] @entity6867 :: ('10', 'Gene') :: ['NAT2'] @entity5553 :: ('D064704', 'Chemical') :: ['levofloxacin'] @entity3109 :: ('MESH:D007538', 'Chemical') :: ['isoniazid'] @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampin'] @entity378 :: ('MESH:D014376', 'Disease') :: ['tuberculosis']
@entity378 :: (MESH:D014376,Disease) :: ['Anti-Tuberculosis']
